Compare
iSpecimen Inc. vs OneMedNet Corp vs Absci Corp vs bioAffinity Technologies, Inc.
| Latest fiscal year | iSpecimen Inc. ISPC | OneMedNet Corp ONMD | Absci Corp ABSI | bioAffinity Technologies, Inc. BIAF |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $1.93M | $1.36M | $2.80M | $6.16M |
| Revenue growth (YoY) | -79.2% | +111.4% | -38.2% | -34.2% |
| Gross margin | 1.2% (computed) | -37.0% | n/a | n/a |
| Operating margin | -465.4% | -711.3% | n/m | -171.6% |
| Net margin | -543.7% | -206.1% | n/m | -242.0% |
| Net income | -$10.49M | -$2.80M | -$115.18M | -$14.91M |
| EPS (Diluted) | -$2.28 | -$0.06 | -$0.84 | -$8.66 |
| Operating cash flow | -$4.24M | -$7.50M | -$92.92M | -$9.33M |
| Free cash flow | -$4.24M | -$7.52M | -$94.03M | -$9.39M |
| Cash & equivalents | $6.88M | $585.0K | $20.02M | $6.45M |
| Total assets | $9.53M | $2.15M | $216.30M | $10.96M |
| Total liabilities | $6.44M | $5.12M | $26.85M | $3.68M |
| Shareholders' equity | $3.09M | -$2.96M | $189.45M | $7.28M |
| Return on year-end equity | -339.6% | n/a | -60.8% | -204.9% |
| Shares outstanding | 8.48M | 51.98M | n/a | 4.50M |
Revenue, most recent five fiscal years
| Fiscal year | iSpecimen Inc. | OneMedNet Corp | Absci Corp | bioAffinity Technologies, Inc. |
|---|---|---|---|---|
| Latest | $1.93M Ended 2025-12-31 | $1.36M Ended 2025-12-31 | $2.80M Ended 2025-12-31 | $6.16M Ended 2025-12-31 |
| 1 year earlier | $9.29M Ended 2024-12-31 | $643.0K Ended 2024-12-31 | $4.53M Ended 2024-12-31 | $9.36M Ended 2024-12-31 |
| 2 years earlier | $9.93M Ended 2023-12-31 | $1.02M Ended 2023-12-31 | $5.72M Ended 2023-12-31 | $2.53M Ended 2023-12-31 |
| 3 years earlier | $10.40M Ended 2022-12-31 | $1.15M Ended 2022-12-31 | $4.53M Ended 2022-12-31 | $6.90M Ended 2022-12-31 |
| 4 years earlier | $11.14M Ended 2021-12-31 | n/a | $4.01M Ended 2021-12-31 | n/a |